Wall Street analyst estimates for CNS Pharmaceuticals, Inc. (CNSP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.27 | ||
| 2026-08-12 | $-0.38 | $-0.24 | -58.3% |
| 2026-05-14 | $-7.30 | $-5.37 | -35.9% |
| 2026-03-31 | $-5.09 | $-5.09 | +0.0% |
| 2025-11-14 | $-5.76 | $-6.63 | +13.1% |
| 2025-08-14 | $-6.42 | $-9.60 | +33.1% |
| 2025-05-15 | $-18.97 | $-24.00 | +21.0% |
| 2025-03-31 | $-447.96 | $-87.96 | -409.3% |
Valuation Ratios
| Price / Book | 2.01 |
| EV / EBITDA | 0.70 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $1955 | $11096 | $13070 | $11756 | $4134 | $3306 | 0 |
| Gross Profit | 0 | 0 | -$1955 | -$11096 | -$13070 | -$11756 | -$4134 | -$3306 | 0 |
| Research & Development | $32638 | $21267 | $1.9M | $5.1M | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M |
| Selling, General & Admin | $182467 | $860520 | $2.0M | $4.4M | $4.7M | $5.6M | $4.8M | $5.6M | $6.2M |
| Operating Expenses | $215105 | $881787 | $3.8M | $9.4M | $14.5M | $14.9M | $18.9M | $14.9M | $16.0M |
| Operating Income | -$516252 | -$881787 | -$3.8M | -$9.5M | -$14.5M | -$14.9M | -$18.9M | -$14.9M | -$16.0M |
| EBITDA | 0 | -$6.5M | -$3.8M | -$9.4M | -$14.5M | -$15.3M | -$18.8M | -$14.8M | -$15.8M |
| Interest Expense | $4257 | $46697 | $44234 | $3264 | $9285 | $7027 | $13805 | $16119 | $15230 |
| Pre-tax Income | -$219362 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$526469 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| EPS | $-11997.00 | $-404415.00 | $-212121.00 | $-512208.00 | $-495027.00 | $-336499.00 | $-150114.00 | $-466.44 | $-35.75 |
| EPS (Diluted) | $-11997.00 | $-404415.00 | $-212121.00 | $-512208.00 | $-495027.00 | $-336499.00 | $-150114.00 | $-466.44 | $-35.75 |
| Shares Outstanding (Diluted) | $18 | $18 | $18 | $18 | $29 | $45 | $126 | $31853 | $443369 |
Price
| Price | $5.50 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CMND · ENSC · GRI · KTTA · NLSP · OGEN · SILO
Explore sector: Healthcare · Biotechnology
More sections of CNSP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks